For example, in a preclinical model, the in vivo maximum efficacy dose of tarlatamab [a half-life extended (HLE) bispecific T-cell engager (BiTE) targeting DLL3] against patient-derived xenograft (PDX) tumor in a T cell-injected model using NOG mice was assessed to be 3 mg/kg14. This evidence concerns the gene DLL3 and neoplasm.